These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Stereoselective synthesis and structure-activity relationship of novel ceramide trafficking inhibitors. (1R,3R)-N-(3-hydroxy-1-hydroxymethyl-3-phenylpropyl)dodecanamide and its analogues. Nakamura Y; Matsubara R; Kitagawa H; Kobayashi S; Kumagai K; Yasuda S; Hanada K J Med Chem; 2003 Aug; 46(17):3688-95. PubMed ID: 12904073 [TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, and X-ray structure of potent memapsin 2 (beta-secretase) inhibitors with isophthalamide derivatives as the P2-P3-ligands. Ghosh AK; Kumaragurubaran N; Hong L; Kulkarni SS; Xu X; Chang W; Weerasena V; Turner R; Koelsch G; Bilcer G; Tang J J Med Chem; 2007 May; 50(10):2399-407. PubMed ID: 17432843 [TBL] [Abstract][Full Text] [Related]
13. Lead identification of 2-iminobenzimidazole antagonists of the chemokine receptor CXCR3. Hayes ME; Breinlinger EC; Wallace GA; Grongsaard P; Miao W; McPherson MJ; Stoffel RH; Green DW; Roth GP Bioorg Med Chem Lett; 2008 Apr; 18(7):2414-9. PubMed ID: 18337097 [TBL] [Abstract][Full Text] [Related]
14. 3,7-Diazadibenzophosphole oxide: a phosphorus-bridged viologen analogue with significantly lowered reduction threshold. Durben S; Baumgartner T Angew Chem Int Ed Engl; 2011 Aug; 50(34):7948-52. PubMed ID: 21732507 [No Abstract] [Full Text] [Related]
15. Pyridine amides as potent and selective inhibitors of 11beta-hydroxysteroid dehydrogenase type 1. Wang H; Ruan Z; Li JJ; Simpkins LM; Smirk RA; Wu SC; Hutchins RD; Nirschl DS; Van Kirk K; Cooper CB; Sutton JC; Ma Z; Golla R; Seethala R; Salyan ME; Nayeem A; Krystek SR; Sheriff S; Camac DM; Morin PE; Carpenter B; Robl JA; Zahler R; Gordon DA; Hamann LG Bioorg Med Chem Lett; 2008 Jun; 18(11):3168-72. PubMed ID: 18485702 [TBL] [Abstract][Full Text] [Related]
16. First structure-activity relationship study on dopamine D3 receptor agents with N-[4-(4-arylpiperazin-1-yl)butyl]arylcarboxamide structure. Leopoldo M; Lacivita E; Colabufo NA; Contino M; Berardi F; Perrone R J Med Chem; 2005 Dec; 48(25):7919-22. PubMed ID: 16335915 [TBL] [Abstract][Full Text] [Related]
17. Structure-guided design of aminopyrimidine amides as potent, selective inhibitors of lymphocyte specific kinase: synthesis, structure-activity relationships, and inhibition of in vivo T cell activation. DiMauro EF; Newcomb J; Nunes JJ; Bemis JE; Boucher C; Chai L; Chaffee SC; Deak HL; Epstein LF; Faust T; Gallant P; Gore A; Gu Y; Henkle B; Hsieh F; Huang X; Kim JL; Lee JH; Martin MW; McGowan DC; Metz D; Mohn D; Morgenstern KA; Oliveira-dos-Santos A; Patel VF; Powers D; Rose PE; Schneider S; Tomlinson SA; Tudor YY; Turci SM; Welcher AA; Zhao H; Zhu L; Zhu X J Med Chem; 2008 Mar; 51(6):1681-94. PubMed ID: 18321037 [TBL] [Abstract][Full Text] [Related]